Associations - MET amplification

MET amplification MET amplification	Non Small Cell Lung Cancer NSCLC	crizotinib Sensitive: A2 - Guideline
MET amplification MET amplification	Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	AMG 102 Resistant: B - Late Trials
MET amplification MET amplification	Gastric Adenocarcinoma Gastric Adenocarcinoma	AMG 102 Resistant: B - Late Trials
MET amplification MET amplification	Non Small Cell Lung Cancer NSCLC	crizotinib + bevacizumab Sensitive: C2 – Inclusion Criteria
MET amplification MET amplification	Non Small Cell Lung Cancer NSCLC	SCC244 Sensitive: C2 – Inclusion Criteria
MET amplification MET amplification	Non Small Cell Lung Cancer NSCLC	gefitinib + CT053PTSA Sensitive: C2 – Inclusion Criteria
MET amplification MET amplification	Non Small Cell Lung Cancer NSCLC	osimertinib + savolitinib Sensitive: C2 – Inclusion Criteria
MET amplification MET amplification	Lung Cancer Lung Cancer	tepotinib Sensitive: C2 – Inclusion Criteria
MET amplification MET amplification	Non Small Cell Lung Cancer NSCLC	APL-101 Sensitive: C2 – Inclusion Criteria
MET amplification MET amplification	Non Small Cell Lung Cancer NSCLC	crizotinib + osimertinib Sensitive: C2 – Inclusion Criteria
MET amplification MET amplification	Non Small Cell Lung Cancer NSCLC	capmatinib Sensitive: C2 – Inclusion Criteria
MET amplification MET amplification	Gastric Cancer Gastric Cancer	savolitinib Sensitive: C2 – Inclusion Criteria
MET amplification MET amplification	Renal Cell Carcinoma RCC	crizotinib Sensitive: C2 – Inclusion Criteria
MET amplification MET amplification	Non Small Cell Lung Cancer NSCLC	tepotinib Sensitive: C2 – Inclusion Criteria
MET amplification MET amplification	Gastric Adenocarcinoma Gastric Adenocarcinoma	crizotinib Sensitive: C3 – Early Trials
MET amplification MET amplification	Non Small Cell Lung Cancer NSCLC	U3-1402 Sensitive: C3 – Early Trials
MET amplification MET amplification	Non Small Cell Lung Cancer NSCLC	Immunotherapy Sensitive: C3 – Early Trials
MET amplification MET amplification	Gallbladder Cancer Gallbladder Cancer	crizotinib Sensitive: C3 – Early Trials
MET amplification MET amplification	Non Small Cell Lung Cancer NSCLC	c-MET inhibitor Sensitive: C3 – Early Trials
MET amplification MET amplification	Colorectal Cancer CRC	TPX-0022 Sensitive: C3 – Early Trials
MET amplification MET amplification	Gastric Cancer Gastric Cancer	TPX-0022 Sensitive: C3 – Early Trials
MET amplification MET amplification	Non Small Cell Lung Cancer NSCLC	gefitinib + savolitinib Sensitive: C3 – Early Trials
MET amplification MET amplification	Non Small Cell Lung Cancer NSCLC	erlotinib Resistant: C3 – Early Trials
MET amplification MET amplification	Solid Tumor Solid Tumor	TQ-B3101 Sensitive: C3 – Early Trials
MET amplification MET amplification	Gastric Cancer Gastric Cancer	crizotinib Sensitive: C3 – Early Trials
MET amplification MET amplification	Lung Adenocarcinoma LUAD	crizotinib + osimertinib Sensitive: C3 – Early Trials
MET amplification MET amplification	Non Small Cell Lung Cancer NSCLC	gefitinib Resistant: C3 – Early Trials
MET amplification MET amplification	GastroEsophageal Cancer GastroEsophageal Cancer	crizotinib Sensitive: C3 – Early Trials
MET amplification MET amplification	Lung Adenocarcinoma LUAD	crizotinib Sensitive: C3 – Early Trials
MET amplification MET amplification	Colorectal Cancer CRC	cetuximab Resistant: C3 – Early Trials
MET amplification MET amplification	Colorectal Cancer CRC	panitumumab Resistant: C3 – Early Trials
MET amplification MET amplification	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	trastuzumab Resistant: C3 – Early Trials
MET amplification MET amplification	Lung Adenocarcinoma LUAD	erlotinib + gefitinib + icotinib Sensitive: C3 – Early Trials
MET amplification MET amplification	GastroEsophageal Cancer GastroEsophageal Cancer	afatinib Resistant: C3 – Early Trials
MET amplification MET amplification	Non Small Cell Lung Cancer NSCLC	osimertinib Resistant: C3 – Early Trials
MET amplification MET amplification	Non Small Cell Lung Cancer NSCLC	lorlatinib Resistant: C3 – Early Trials
MET amplification MET amplification	Sarcoma Sarcoma	crizotinib Sensitive: C3 – Early Trials
MET amplification MET amplification	Pancreatic Cancer Pancreatic Cancer	cetuximab Resistant: C4 – Case Studies
MET amplification MET amplification	Biliary Tract Cancer Biliary Tract Cancer	crizotinib Sensitive: C4 – Case Studies
MET amplification MET amplification	Cholangiocarcinoma Cholangiocarcinoma	c-MET inhibitor Sensitive: C4 – Case Studies
MET amplification MET amplification	Glioblastoma GBM	crizotinib Sensitive: C4 – Case Studies
MET amplification MET amplification	Glioblastoma GBM	cediranib Resistant: C4 – Case Studies
MET amplification MET amplification	Gastric Adenocarcinoma Gastric Adenocarcinoma	RG3638 Sensitive: C4 – Case Studies
MET amplification MET amplification	Non Small Cell Lung Cancer NSCLC	selpercatinib Resistant: C4 – Case Studies
MET amplification MET amplification	Head and Neck Cancer Head and Neck Cancer	crizotinib Sensitive: C4 – Case Studies
MET amplification MET amplification	Hepatocellular Cancer HCC	crizotinib Sensitive: C4 – Case Studies
MET amplification MET amplification	Non Small Cell Lung Cancer NSCLC	osimertinib + HQP8361 Sensitive: D – Preclinical
MET amplification MET amplification	Non Small Cell Lung Cancer NSCLC	HQP8361 Sensitive: D – Preclinical
MET amplification MET amplification	Non Small Cell Lung Cancer NSCLC	CKD-702 Sensitive: D – Preclinical
MET amplification MET amplification	Non Small Cell Lung Cancer NSCLC	afatinib Resistant: D – Preclinical
MET amplification MET amplification	Gastric Cancer Gastric Cancer	JNJ-38877605 Sensitive: D – Preclinical
MET amplification MET amplification	Gastric Cancer Gastric Cancer	SGX523 Sensitive: D – Preclinical